Exosome Diagnostics,Inc., the developer of a revolutionary liquid biopsy platform that enables non ‐ invasive detection of clinical biomarkers, potentially obviating the need for tissue biopsy, today announced new positive data recently presented at the ASCO 2016 Genitourinary Cancers Symposium (January 7 ‐ 9, San Francisco, California). These data from a prospective clinical study add to a growing body of clinical validation evidence demonstrating ExoDx™ Prostate(IntelliScore), the company’s completely non ‐ invasive urine ‐ based liquid biopsy for prostate cancer, has the unique ability to accurately identify high ‐ grade prostate cancer (HGPCA) both at the time of biopsy and at surgery. These data demonstrate the potential for this first- in‐class exosomal RNA (exoRNA) ‐ based assay to be utilized throughout the care continuum, including prior to initial biopsy, as well as for sequential monitoring of disease progression in patients enrolled in active surveillance.